3 Pharmaceutical Company, Fertilisers and Industrial Chemicals Maker and Power Generation Giant Stocks With a Strong Future Roadmap: Strides Pharma Science, Deepak Fertilisers and NTPC
- November 10, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Strides Pharma Science, Deepak Fertilisers and NTPC: ROE of 10.8% to 17.9% and FY22 to FY26 revenue CAGR of 8.9% to 11.8%. Prices as of 9 Nov 2026.
Quick Answer
The three pharma, fertiliser and power giant stocks to watch are Strides Pharma Science, Deepak Fertilisers and NTPC. Their return on equity ranges from 10.8% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.9% to 11.8%. Strides Pharma Science leads on both return on equity at 17.9% and revenue growth at 11.8% a year. Prices are based on the 9 November 2026 close, and this article is educational, not investment advice.
Pharma, fertiliser and power giant stocks bring together companies with a visible plan for the years ahead. Strides Pharma Science, Deepak Fertilisers and NTPC cover a pharmaceutical company, a fertilisers and industrial chemicals maker and a power generation giant.
This list covers three pharma, fertiliser and power giant stocks with complete current figures: Strides Pharma Science, Deepak Fertilisers and NTPC. Every figure comes from the latest reported financials and the 9 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, Fertiliser and Power Giant Stocks?
Pharma, fertiliser and power giant stocks are listed companies that develop and sell generic and specialty medicines, make fertilisers and industrial chemicals such as ammonium nitrate, and generate electricity from thermal, hydro and renewable plants. Their earnings depend on medicine demand, farm and mining chemical use and power output.
Pharma, Fertiliser and Power Giant Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Strides Pharma Science | 1,035.9 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
| Deepak Fertilisers | 1,155 | 14,354 | 14.6 | 33.2 | 10.8 | 0.83 |
| NTPC | 322.7 | 292,694 | 10.3 | 21.3 | 13.3 | 1.33 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing pharma, fertiliser and power giant stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma, Fertiliser and Power Giant Stocks Have a Strong Roadmap in India?
Pharma, fertiliser and power giant stocks have a strong roadmap in India because steady global demand for medicines, rising farm and mining needs and growing electricity consumption keep widening the market for these companies.
- Pharma. Global markets need affordable medicines.
- Fertilisers. Farms and mines need chemical inputs.
- Power generation. Demand for electricity keeps rising.
Why Strides Pharma Science Features Among These Pharma, Fertiliser and Power Giant Stocks
Among the pharma, fertiliser and power giant stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%.
In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Why Deepak Fertilisers Features Among These Pharma, Fertiliser and Power Giant Stocks
Among the medicine, crop nutrient and electricity shares on this list, Deepak Fertilisers and Petrochemicals makes industrial chemicals such as ammonium nitrate and nitric acid for mining and industry, along with crop nutrients and fertilisers sold to farmers.
In the June 2026 quarter, revenue grew 21.6% year on year to Rs 3,262 crore, while net profit rose 101.0% to Rs 490 crore. Revenue rose from Rs 7,707 crore in FY22 to Rs 11,609 crore in FY26, a compound annual growth rate of 10.8%.
Net profit grew from Rs 468 crore in FY24 to Rs 739 crore in FY26, which works out to a compound annual growth rate of 25.7%. The company has a return on equity of 10.8%, a debt to equity ratio of 0.83 and a market capitalisation of Rs 14,354 crore. The stock trades at a P/E of 14.6, below the industry P/E of 33.2.
Roadmap: The company is expanding its chemical capacity for mining and industrial customers, which supports higher-value sales. Growing mining and infrastructure activity increases demand for its products.
What to watch: Follow mining demand, gas costs and progress on new chemical plants.
Why NTPC Features Among These Pharma, Fertiliser and Power Giant Stocks
Among the three companies on this list, NTPC is India’s largest power generation company, with thermal, hydro and renewable plants and a growing pipeline of green energy projects.
The company has a return on equity of 13.3%, a debt to equity ratio of 1.33 and a market capitalisation of Rs 292,694 crore. The stock trades at a P/E of 10.3, below the industry P/E of 21.3.
Revenue rose from Rs 134,994 crore in FY22 to Rs 189,799 crore in FY26, a compound annual growth rate of 8.9%. Net profit grew from Rs 15,474 crore in FY22 to Rs 30,010 crore in FY26, which works out to a compound annual growth rate of 18.0%. In the June 2026 quarter, revenue grew 6.9% year on year to Rs 51,142 crore, while net profit rose 12.9% to Rs 6,896 crore.
Roadmap: The company is adding thermal capacity to meet rising electricity demand while building a large renewable portfolio. Long-term power purchase agreements give it steady visibility.
What to watch: Follow capacity additions, renewable progress and plant availability.
Strides Pharma Science vs Deepak Fertilisers vs NTPC on Key Financials
The table below sets the three pharma, fertiliser and power giant stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
| Deepak Fertilisers | 7,707 | 11,609 | 10.8% | 739 | 6.4% |
| NTPC | 134,994 | 189,799 | 8.9% | 30,010 | 15.8% |
Strides Pharma Science posts the highest return on equity in this group at 17.9%. NTPC has the largest FY26 revenue at Rs 189,799 crore, and Strides Pharma Science shows the fastest revenue growth with a 11.8% compound annual rate. A useful habit with pharma, fertiliser and power giant stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Strides Pharma Science | 1,128 | 1,270 | 12.6% |
| Deepak Fertilisers | 2,683 | 3,262 | 21.6% |
| NTPC | 47,821 | 51,142 | 6.9% |
Key Risks to Check Before Investing in Pharma, Fertiliser and Power Giant Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, fertiliser and power giant stocks, the main points are: Long-term medicine, crop nutrient and electricity shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Fuel and power prices. Tariffs and fuel costs can influence earnings.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, fertiliser and power giant stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, Fertiliser and Power Giant Stocks
Pharma, fertiliser and power giant stocks suit investors who prefer to study business strength before price moves. Strides Pharma Science, Deepak Fertilisers and NTPC each have a clear plan to grow. Based on the 9 November 2026 close, Strides Pharma Science trades at Rs 1,035.9, Deepak Fertilisers at Rs 1,155 and NTPC at Rs 322.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma, fertiliser and power giant stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma, fertiliser and power giant stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, fertiliser and power giant stocks?
Ans. Pharma, fertiliser and power giant stocks are listed companies that develop and sell generic and specialty medicines, make fertilisers and industrial chemicals such as ammonium nitrate, and generate electricity from thermal, hydro and renewable plants. Their earnings depend on medicine demand, farm and mining chemical use and power output. This list looks at three of them, Strides Pharma Science, Deepak Fertilisers and NTPC, using reported FY22 to FY26 financials and the 9 November 2026 closing prices.
Which pharma, fertiliser and power giant stocks are covered in this list?
Ans. This list covers Strides Pharma Science, Deepak Fertilisers and NTPC. Based on the 9 November 2026 close, Strides Pharma Science traded at Rs 1,035.9, Deepak Fertilisers at Rs 1,155 and NTPC at Rs 322.7. Their return on equity ranges from 10.8% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.9% to 11.8%.
Why do pharma, fertiliser and power giant stocks have a strong future roadmap in India?
Ans. Pharma, fertiliser and power giant stocks have a strong roadmap in India because steady global demand for medicines, rising farm and mining needs and growing electricity consumption keep widening the market for these companies. The main drivers are as follows. Pharma. Global markets need affordable medicines. Fertilisers. Farms and mines need chemical inputs. Power generation. Demand for electricity keeps rising. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
How has Deepak Fertilisers performed financially?
Ans. Revenue rose from Rs 7,707 crore in FY22 to Rs 11,609 crore in FY26, a compound annual growth rate of 10.8%. Net profit grew from Rs 468 crore in FY24 to Rs 739 crore in FY26, which works out to a compound annual growth rate of 25.7%. In the June 2026 quarter, revenue grew 21.6% year on year to Rs 3,262 crore, while net profit rose 101.0% to Rs 490 crore. The company has a return on equity of 10.8%, a debt to equity ratio of 0.83 and a market capitalisation of Rs 14,354 crore. The stock trades at a P/E of 14.6, below the industry P/E of 33.2. Looking ahead, the company is expanding its chemical capacity for mining and industrial customers, which supports higher-value sales. Growing mining and infrastructure activity increases demand for its products.
How has NTPC performed financially?
Ans. Revenue rose from Rs 134,994 crore in FY22 to Rs 189,799 crore in FY26, a compound annual growth rate of 8.9%. Net profit grew from Rs 15,474 crore in FY22 to Rs 30,010 crore in FY26, which works out to a compound annual growth rate of 18.0%. In the June 2026 quarter, revenue grew 6.9% year on year to Rs 51,142 crore, while net profit rose 12.9% to Rs 6,896 crore. The company has a return on equity of 13.3%, a debt to equity ratio of 1.33 and a market capitalisation of Rs 292,694 crore. The stock trades at a P/E of 10.3, below the industry P/E of 21.3. Looking ahead, the company is adding thermal capacity to meet rising electricity demand while building a large renewable portfolio. Long-term power purchase agreements give it steady visibility.
What risks should investors check before buying pharma, fertiliser and power giant stocks?
Ans. Investors should check a few risks before buying pharma, fertiliser and power giant stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Fuel and power prices. Tariffs and fuel costs can influence earnings. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, fertiliser and power giant stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 9 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
